-
Get the latest information and research on osteoporosis.
-
Find treatment, guidance and advice on living with osteoporosis.
-
Share your experience and get involved. Joining the conversation is the first step to ending osteoporosis and broken bones.
NOF
April 5, 2012
DXA Not Necessary for Women Under Age 65 and Men Under Age 70 with No Osteoporosis Risk Factors, but Remains Widely Underutilized among those with Highest Fracture Risk.
NOF
Washington, DC
April 4, 2012
DXA Not Necessary for Women Under Age 65 and Men Under Age 70 with No Osteoporosis Risk Factors, but Remains Widely Underutilized among those with Highest Fracture Risk
FDA
March 22, 2012
The U.S. Food and Drug Administration (FDA) has approved the first generic versions of Boniva® (ibandronate), a once-monthly prescription tablet used for the prevention and treatment of osteoporosis in women after menopause. Ibandronate is in a class of drugs called bisphosphonates that help increase bone mass and reduce the chance of broken bones.
NOF
February 24, 2012
Congress did not include an extension of the current Medicare reimbursement rates for DXA in the Middle Class Tax Relief and Job Creation Act, H.R. 3630. Despite a strong advocacy effort carried out by NOF and the DXA Coalition in contacting Members of Congress, as well as strong bipartisan support among many of the House and Senate conferees who negotiated the tax package, there was some opposition to extending the current Medicare reimbursement rates for DXA, resulting in the provisions being eliminated from the final package.
NOF
January 24, 2012
NOF Responds to Media Coverage of the New England Journal of Medicine study “Bone-Density Testing Interval and Transition to Osteoporosis in Older Women” and Encourages Current Patients to Continue Working with their Healthcare Providers to Regularly Monitor their Condition
NOF
December 6, 2011
A new study published this week in the December issue of Health Affairs looked at the impact cuts in Medicare Part B reimbursement have had on access and utilization of DXA testing, the imaging procedure accepted as the gold standard for diagnosing osteoporosis. The study found that after a decade of growth, DXA testing in all Part B settings was stagnant from 2007-2009, resulting in 800,000 fewer tests than expected for Medicare beneficiaries, which if conducted, may have prevented approximately 12,000 fractures.
NOF
September 13, 2011
ORAL REMARKS – NOF President Robert R. Recker - FDA – September 9, 2011
Good afternoon. I am Dr. Robert Recker, director of the Osteoporosis Research Center at Creighton University in Omaha, Nebraska and am here as president of the National Osteoporosis Foundation, the leading consumer and community-focused health organization dedicated to the prevention of osteoporosis and broken bones.
NOF
September 9, 2011
In this letter, NOF President, Dr. Robert R. Recker, commends the FDA for examining the benefits and risks of long term bisphosphonate use and lays out NOF’s hope that its recommendations will help patients and their healthcare providers better understand the benefits and significant risks of the widely prescribed medications.
FDA
September 8, 2011
The FDA has issued new warning label information for the osteoporosis drug zoledronic acid (Reclast) indicating that the drug should not be used in patients with significant renal impairment and stating that physicians should screen patients for kidney dysfunction before starting them on the drug. The FDA also identifies risk factors that physicians should take into consideration when prescribing Reclast including advanced age, concurrent treatment with other nephrotoxic drugs, and dehydration secondary to fever, sepsis, gastrointestinal losses or diuretic therapy.
NOF
July 6, 2011
As the administration works to implement the Affordable Care Act, there are several regulatory proposals on the horizon. NOF highlighted the need for osteoporosis care for men and women after they have broken a bone in its comments on one such proposal which would affect access to quality care for Medicare patients.
